This is after the satisfactory evaluation of the corrective actions taken by the company in response to the Warning Letter that was issued on November 6, 2017.“We are pleased to be informed by the USFDA that we have addressed the concerns through our corrective actions related to the November 2017 Warning Letter,” said Nilesh Gupta, MD of Lupin.”We are committed to being compliant with good manufacturing practices, and to uphold global quality standards and ensuring the quality of our products,” Gupta added.ET on early this month reported that Lupin’s establishment inspection report (EIR) from the USFDA with a voluntary action indicated (VAI) status for its Pithampur Unit-2 facility in Madhya Pradesh will pave the way for possible lifting of warning letters on the facility.Shares of Lupin rose 4.09% to close at Rs 980.05 on BSE on Thursday, while the benchmark Sensex declined 0.66% to end 66,266.82 points.Experience Your Economic Times Newspaper, The Digital Way!Read Complete Print Edition »Front PagePure PoliticsCompaniesET MarketsMoreOil firms, govt are earning well. But you may still have to pay high fuel pricesIndia to meet 76 pc electricity requirement in 2023-24 from thermal power plantsBharat Biotech picks up 20 per cent stake in Eastman Exports Global ClothingAdani lenders weigh up to $750 million loan for Ambuja debtHindustan Power Exchange gets CERC nod for high price contracts in 3 key marketsSemiconductor PLI worth $10 bn to help India do in a decade what China did in 25-30 years: Rajeev ChandrasekharEmami Agrotech passes on benefits of input cost cuts to consumersAir India to start Delhi-Dhaka direct flights from Sept 15Delhi High Court calls for periodic audit of safety, security in Indian RailwaysMyntra growth doubles in ethnic wear; major contribution from metros and tier-1 cities